Imagine a smart app that reads heart scans like a world-class expert. It can spot a dangerous heart attack that current methods often miss, and it does so nearly 3 hours faster. It works with any existing heart monitor, meaning hospitals don't need to buy new expensive machines to use it.
Current heart attack diagnostic criteria miss about 50% of obstructive myocardial infarction cases. This leads to delayed treatments and high rates of unnecessary invasive procedures.
An AI-powered mobile application and a patented digitization system that converts any ECG image into a digital waveform for rapid diagnosis.
If you are a hospital dealing with 50M annual chest pain visits — this project developed an AI model that is twice as sensitive as traditional methods. It reduces missed heart attack diagnoses by 50%, ensuring patients get to the catheterization lab faster.
If you are a software provider dealing with fragmented diagnostic tools — this project developed a mobile application that integrates with any ECG device. It converts paper or screen images into digital waveforms for immediate AI analysis.
If you are a device maker dealing with outdated diagnostic criteria — this project developed an AI layer that works with any hardware. It allows your existing machines to detect heart attacks 2.9 hours faster without requiring hardware upgrades.
Based on available project data, specific pricing or cost structures are not disclosed; however, the project aims to reduce overall healthcare expenses by decreasing unnecessary invasive procedures.
Yes, the tool is designed for global scale as it requires no additional hardware and is compatible with any ECG device and healthcare infrastructure.
The technology includes a patented ECG digitization system that converts paper-form or screen-based images into digital waveforms.
The model is designed for seamless integration with all healthcare provider systems, allowing implementation without disrupting existing workflows.
The project period runs from 2024-01-01 to 2026-06-30, focusing on completing the AI model, conducting a randomized controlled trial, and obtaining regulatory approval.
The project is led by a single Slovakian SME, POWERFUL MEDICAL SRO. With a 100% industry ratio and a total EU contribution of EUR 2,499,999, the project is lean and commercially driven, focusing on rapid development and regulatory scaling rather than academic research.
Contact POWERFUL MEDICAL SRO in Slovakia for licensing and integration inquiries.
Contact us to explore partnership opportunities with this AI diagnostic leader.
